← Leaderboards
Alan L. Buchman
University Of Texas Hlth Sci Ctr Houston
$204,144
Attributed
$204,144
Total exposure
9
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $76K · FY2005–07$100K$75K$50K$25K$0
'05
'06
'07
Funding mix
By agency
NIH$204,144 · 9
By mechanism
M01$204,144 · 9
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Sci Ctr Houston
Same institution · by research overlap
- Wa Xian$4,191,802
- Martin Lee Blakely$5,204,299
- Frank G Moody$853,471
- Kai Sun$3,820,400
- Eugenie S Kleinerman$6,577,718
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHuman Therapy EvaluationClinical ResearchGastrointestinal Disorder ChemotherapyDrug Screening /EvaluationCrohn'S DiseaseGastrointestinal AgentsUlcerative ColitisCell Adhesion MoleculesCorticosteroidsDrug Administration Rate /DurationDrug Administration RoutesDrug ToleranceHyperbaric Oxygen TherapyInhibitor /AntagonistInterleukin 10Longitudinal Human StudyPharmacokineticsRelapse /RecurrenceSign /SymptomWeaningRemission /RegressionParenteral FeedingsQuality Of Life
Grant awards (15)
TREATMENT OF HEPATIC STEATOSIS ASSOCIATED WITH TOTAL PARENTAL NUTRITION$10,967
M01 · FY2007 · RR · contact PI
USE OF CLONIDINE TO REDUCE DIARRHEA LOSSES IN PATIENTS WITH PROXIMAL JEJUNOSTOMY$45,614
M01 · FY2006 · RR · contact PI
USE OF CLONIDINE TO REDUCE DIARRHEA LOSSES IN PATIENTS WITH PROXIMAL JEJUNOSTOMY$75,979
M01 · FY2005 · RR
SAFETY AND EFFICACY OF ISIS 2302 IN STEROID DEPENDENT CROHN'S DISEASE$0
M01 · FY2002 · RR
Hyperbaric oxygen therapy for severe ulcerative colitis$0
M01 · FY2002 · RR
SUBCUTANEOUS RHUIL 10 IN SUBJECTS W/ STEROID DEPENDENT CROHNS DISEASE$0
M01 · FY2002 · RR
SUBCUTANEOUS RHUIL 10 IN SUBJECTS W/ STEROID DEPENDENT CROHNS DISEASE$0
M01 · FY2001 · RR
SAFETY AND EFFICACY OF ISIS 2302 IN STEROID DEPENDENT CROHN'S DISEASE$0
M01 · FY2001 · RR
Hyperbaric oxygen therapy for severe ulcerative colitis$0
M01 · FY2001 · RR
BUDESONIDE CONTROLLED RELEASE CAPSULES AS MAINTENANCE IN CROHN'S DISEASE$15,114
M01 · FY2000 · RR
SAFETY AND EFFICACY OF ISIS 2302 IN STEROID DEPENDENT CROHN'S DISEASE$15,114
M01 · FY2000 · RR
USE OF INTRAVENOUS CHOLINE IN TOTAL PARENTERAL NUTRITION (TPN)$15,114
M01 · FY2000 · RR
LONGTERM TOLERABILITY, SAFETY AND EFFICACY OF ORAL RIDOGREL IN ULCERATIVE COLITIS$15,114
M01 · FY2000 · RR
SUBCUTANEOUS RHUIL 10 IN SUBJECTS W/ STEROID DEPENDENT CROHNS DISEASE$11,128
M01 · FY2000 · RR
Hyperbaric oxygen therapy for severe ulcerative colitis$0
M01 · FY2000 · RR